Filing Flows › Comparisons › LMRI vs VCYT
Lumexa Imaging Holdings vs Veracyte: LMRI and VCYT compared
Lumexa Imaging Holdings is the larger company: $264M of revenue in its latest quarter (Q2 2026) against $152M for Veracyte (Q3 2026). Veracyte is growing faster (+15% against +5% a year earlier). Veracyte is more profitable, with an operating margin of 10.9% against 8.7%.
Where the money goes: LMRI and VCYT
Lumexa Imaging Holdings (LMRI) · Q2 2026
Lumexa Imaging Holdings, Q2 2026: revenue $264M (+5% year over year), operating margin 8.7%, net earnings $2.7M, operating cash flow $32.8M. The chart follows the revenue to costs, profit and cash.
Veracyte (VCYT) · Q3 2026
Veracyte, Q3 2026: revenue $152M (+15% year over year), operating margin 10.9%, net earnings $31.5M, operating cash flow $40.3M. The chart follows the revenue to costs, profit and cash.
| Lumexa Imaging Holdings (LMRI) | Veracyte (VCYT) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $264M | $152M |
| Revenue growth, Y/Y | +5% | +15% |
| Gross margin | — | 70.6% |
| Operating margin | 8.7% | 10.9% |
| Net earnings | $2.7M | $31.5M |
| Net margin | 1.0% | 20.8% |
| Operating cash flow | $32.8M | $40.3M |
| Free cash flow | $23.1M | $37.9M |
| Market value | — | $3.7B |
| P/E | — | 32.4× |
| Analysts’ mean target | — | $57.40 |
Where the revenue comes from
Lumexa Imaging Holdings
- Health Care Patient Service: $195M (74%)
- Management Fee and Other Revenue Related Party: $51.7M (20%)
- Patient Service Revenue Related Party: $8.8M (3%)
- Investment Advisory Management and Administrative Service: $8.7M (3%)
Veracyte
- Testing revenue: $146M (96%)
- Product revenue: $4.6M (3%)
- Biopharmaceutical and other revenue: $709K (0%)
Questions
Which is bigger, Lumexa Imaging Holdings or Veracyte?
Lumexa Imaging Holdings is the larger company: $264M of revenue in its latest quarter (Q2 2026) against $152M for Veracyte (Q3 2026).
Is Lumexa Imaging Holdings or Veracyte growing faster?
Veracyte is growing faster (+15% against +5% a year earlier).
Which is more profitable, Lumexa Imaging Holdings or Veracyte?
Veracyte is more profitable, with an operating margin of 10.9% against 8.7%.
More: Lumexa Imaging Holdings earnings · how Lumexa Imaging Holdings makes money · Veracyte earnings · how Veracyte makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.